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Abstract
Background: The impact of travel distance on stage at presentation and manage-
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ment strategies of laryngeal squamous cell carcinoma (SCC) is unknown. We investigated this relationship.
Methods: Retrospective review of patients with laryngeal SCC in the National
Cancer Data Base from 2004 to 2016. Multivariate analysis determined relationships
between travel distance, sociodemographic, geographic, and hospital factors. Logistic regression determined the influence of travel distance on T‐stage and overall
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stage at presentation, and receipt of total laryngectomy.
Results: Sixty thousand four hundred and thirty‐nine patients were divided into
groups based on distance to treatment: short (<12.5 miles); intermediate (12.5–49.9
miles); and long (>50 miles). Increased travel was associated with T4‐stage (intermediate vs. short OR 1.11, CI 1.04–1.18, p = 0.001; long vs. short OR 1.5, CI
1.36–1.65, p < 0.001), and total laryngectomy (intermediate vs. short OR 1.40, CI
1.3–1.5, p ≤ 0.001; long vs. short OR 2.52, CI 2.28–2.79, p ≤ 0.001). In T4 disease,
total laryngectomy was associated with improved survival compared to nonsurgical
treatment (HR 0.75, CI 0.70–0.80, p < 0.001) regardless of travel distance.
Conclusion: Longer travel distance to care is associated with increased stage at
presentation, rate of laryngectomy, and improved survival in advanced laryngeal
SCC. Health policy efforts should be directed towards improving early access to
diagnosis and care.
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| INTRODUCTION

centralization of cancer care at larger institutions. Recent studies
among patients with pancreatic, esophageal and colorectal cancer

Increased travel distance affects patient access to and use of

have provided evidence of increases in travel distance to care

health care and may potentially result in delays in diagnosis and

secondary to centralization.

16

treatment. Numerous studies have described the adverse effects

Among head and neck cancer patients, research efforts have

of increased travel distance on disease related outcomes for

been primarily aimed at identifying and addressing disparities in

colorectal, ovarian, breast, esophageal, skin, and metastatic can-

health care with particular focuses on racial and economic

cers.

1–15

The association between travel distance and disease‐

related outcomes is particularly important given trends towards
J Surg Oncol. 2021;1–12.

factors.

15,17–25

Additionally, other studies have sought to

determine factors prolonging the time between diagnosis and
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treatment of head and neck squamous cell carcinoma (HNSCC),

2 |
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METHODS

with particular attention on stage at diagnosis, primary treatment
modality, and need for diagnostic biopsy or imaging.

26

There is

2.1 |

Data source

evidence to support the notion that ease of access to a specialist
is protective against late stage diagnoses in patients with
HNSCC.

27

Patients were identified from the National Cancer Database (NCDB)

However, the effect of travel distance (distance to

Participant User File (PUF). The NCDB is a joint project between the

care or the time it takes a patient to reach care) on stage at

American College of Surgeons and the American Cancer Society,

presentation of laryngeal cancer and receipt of total lar-

providing information on approximately 70% of cancer diagnoses in

yngectomy remains unknown. Travel distance is especially im-

the United States annually. The source files were used in accordance

portant to patients with laryngeal cancer, as those patients who

with the NCDB Participant User Files (PUF) data use agreement. This

present with advanced stage disease are more likely to receive

study was given an IRB waiver by Memorial Sloan Kettering Cancer

total laryngectomy as opposed to organ preservation therapy.

Center IRB.

The purpose of this study was to assess the relationship between
travel distance, stage at presentation, and treatment modality among
patients with laryngeal cancer. We hypothesized that increased travel

2.2 |

Patient selection

distance is associated with increased stage at presentation of laryngeal
squamous cell carcinoma (SCC), and may also be associated with receipt

We identified patients who were diagnosed with laryngeal

of total laryngectomy. Lastly, as an exploratory analysis, we examined the

squamous cell carcinoma from 2004 to 2016. Full inclusion cri-

impact of travel distance and treatment modality on survival.

teria are shown in Figure 1. Inclusion dates were chosen such that

FIGURE 1

CONSORT diagram
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there was an adequate sample size to power the analysis.

2.4 |

3

Analysis

Squamous cell histology was identified from International Classification

codes

Patient, tumor, and treatment characteristics were summarized as

(8070–8078). Patients with pathologic or clinical stage zero dis-

of

Diseases

for

Oncology

morphological

proportions and compared between travel distance groups via χ2

ease were excluded, as were patients with unknown overall

analysis. Patient, tumor, and treatment characteristics were examined

clinical stage or clinical T stage. We also excluded patients with

for association with travel distance by multivariable logistic regres-

an unconfirmed diagnosis, unknown treatment modality, non‐

sion, additionally controlling for year of diagnosis. This analysis was

external beam radiotherapy, not all treatment at reporting facility,

repeated analyzing the association between travel distance and tu-

missing survival data, and patients living >250 miles from the

mor stage at presentation. Travel distance was then assessed for

treating center. Patient location‐based data, but not hospital

association with receipt of total laryngectomy, controlling for patient,

distance, is suppressed in the NCDB for all cases <40 years and

tumor, and treatment‐related characteristics. The laryngectomy rate

therefore were labelled as missing for this analysis.

for each institution was calculated and institutional laryngectomy
frequency was classified by quartiles. The above analysis was repeated controlling for institutional laryngectomy rate. The association

| Variables

2.3

between survival and travel distance, tumor stage, N stage, clinical
stage, and the interaction between tumor stage and travel distance

Patient data, including patient demographics (sex, age, race,

was estimated using Cox regression analysis. Survival was estimated

Charlson‐Deyo Comorbidity Score, insurance type, urban status,

using Kaplan Meier curves. A post hoc analysis was performed to

education, and income), tumor characteristics (primary site, clinical

determine the effect of travel distance on survival. A p‐value <0.05

stage, and metastases), and treatment characteristics (hospital type,

was considered significant. Analyses were conducted using Stata

hospital location, hospital volume, treatment modality, and receipt of

Statistical Software (Release 12.1; Stata Inc.).

laryngectomy) were collected for each patient. Patients were classified as treated with primary surgery or radiation based on whichever
treatment was administered first. Of note, the NCDB does provide

3 |

RESULTS

dosage data for patients undergoing radiation therapy, however, the
availability of this data varies greatly within the database and does

3.1 |

Baseline characteristics

not permit analysis of this variable. Patients were only included if
they underwent primary laryngectomy, definitive radiotherapy, or

Sixty thousand four hundred and thirty‐nine patients with histologi-

definitive concurrent chemoradiation therapy. Patients receiving

cally confirmed laryngeal SCC were identified and included in the

salvage laryngectomy were excluded from the analysis as the NCDB

analysis. Patient characteristics are shown in Table 1. Overall, 78% of

does not provide longitudinal data on patients and the currently

patients were male, 79% were Caucasian, and 43% of patients were

available data does not allow evaluation of patients requiring salvage

50–64 years old. Most patients were treated at an academic hospital

treatment from the initial cohort. Comorbidities are classified in

(40%) or a comprehensive community center (39%). Median hospital

terms of Charlson‐Deyo comorbidity score, summarized as 0, 1, 2, or

volume was 91 cases of laryngeal cancer per year (interquartile range

>2. Hospital volume was defined as the total number of laryngeal

[IQR 48–86]). 66% of patients were treated with primary radiation

cancer cases treated in the time frame included in analysis and

and 34% were treated with primary surgery. Thirty four thousand

classified into quartiles. Hospital location was simplified into north-

nine hundred and forty‐three patients (58%) lived within 12.5 miles

east (New England, Mid‐Atlantic), southeast (South Atlantic), central

of the treating hospital, 19,554 (32%) within 12.5–49.9 miles, and

(East North Central, East South Central, West North Central, West

5942 (10%) patients lived 50 or more miles from the treating hospital.

South Central) and west (Pacific, Mountain). Patients were classified

Overall, 12% of included patients underwent total laryngectomy.

as living in a city, urban, or rural environment based on living in an
area of >250,000 people, 2500–20,000, or <2500, respectively. Institutional laryngectomy rates were calculated and stratified into

3.2 |

Factors associated with travel distance

quartiles.
Patient travel distance is pre‐calculated in the NCDB as the

When controlling for patient, tumor, and treatment factors, patients

number of miles traveled from the center of a patient's zip code

were more likely to have a long travel distance if they were male,

of residence to the center of the zip code of the treating hospital.

Caucasian, had a Charlson‐Deyo comorbidity score of 0, lived in a

Following previously published literature on travel distance, three

rural location, lived in a zip code with lower educational attainment,

patient groups were created based on travel distance: short

were treated at an academic/NCI‐designated cancer center, were

(<12.5 miles); intermediate (12.5–49.9 miles); and long (≥50

treated outside of the northeast, or were treated at higher‐volume

miles).

6

hospitals (p < 0.001 for all).

4
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<12.5 miles

12.5–49.9
miles

>50 miles

Total

Male

27,216 (57%)

15,471 (33%)

4729 (10%)

47,416

Female

7727 (59%)

4083 (31%)

1213 (9%)

13,023

White

25,949 (54%)

16,840 (35%)

5087 (11%)

47,876

Black

6283 (73%)

1825 (21%)

519 (6%)

8627

Hispanic

1802 (74%)

488 (20%)

146 (6%)

2436

Other

909 (61%)

401 (27%)

190 (13%)

1500

<50 years

2983 (54%)

1841 (33%)

699 (13%)

5523

50–64 years

14,336 (55%)

8803 (34%)

2787 (11%)

25,926

65–79 years

13,545 (59%)

7362 (32%)

2085 (9%)

22,992

80 years or more

4079 (68%)

1548 (26%)

371 (6%)

5998

0

25,110 (58%)

14,228 (33%)

4246 (10%)

43,584

1

7041 (58%)

3889 (32%)

1250 (10%)

12,180

2

2013 (59%)

1046 (31%)

338 (10%)

3397

≥3

779 (61%)

391 (31%)

108 (8%)

1278

Private

1790 (55%)

1086 (33%)

390 (12%)

3266

Uninsured

11,198 (57%)

6709 (34%)

1785 (9%)

19,692

Medicaid

3857 (59%)

1931 (29%)

800 (12%)

6588

Medicare/Gov

17,425 (59%)

9399 (32%)

2829 (10%)

29,653

Unknown

673 (54%)

429 (35%)

138 (11%)

1240

City

32,370 (69%)

12,270 (26%)

2057 (4%)

46,697

Urban

1874 (17%)

6021 (55%)

3118 (28%)

11,013

Rural

25 (2%)

914 (58%)

635 (40%)

1574

Unknown

674 (58%)

349 (30%)

132 (11%)

1155

<20% with HS
degree

18,679 (63%)

8844 (30%)

2275 (8%)

29,798

>20% without HS
degree

15,572 (53%)

10,150 (35%)

3479 (12%)

29,201

Unknown

692 (48%)

560 (39%)

188 (13%)

1440

>$30000

27,975 (59%)

15,859 (33%)

3942 (8%)

47,776

<$30,000

6280 (56%)

3137 (28%)

1813 (16%)

11,230

Unknown

688 (48%)

558 (39%)

187 (13%)

1433

Characteristic
Sex

Race

Age

Charlson comorbidity score

Insurance status

Urban status

Education attainment

Income

ET AL.

T A B L E 1 Baseline characteristics of
patient cohort
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<12.5 miles

12.5–49.9
miles

>50 miles

Total

Academic/NCI CCC

12,527 (51%)

7764 (32%)

4112 (17%)

24,403

Community Center

3472 (65%)

1763 (33%)

120 (2%)

5355

CC

13,950 (60%)

8045 (35%)

1274 (5%)

23,269

INCC

4675 (69%)

1782 (26%)

340 (5%)

6797

Unknown

319 (52%)

200 (33%)

96 (16%)

615

Northeast

8824 (69%)

3444 (27%)

523 (4%)

12,791

Southeast

7616 (55%)

5010 (36%)

1190 (9%)

13,816

Central

14,244 (53%)

9108 (34%)

3411 (13%)

26,763

West

3940 (61%)

1792 (28%)

722 (11%)

6454

Unknown

319 (52%)

200 (33%)

96 (16%)

615

1–44

10,948 (70%)

4093 (26%)

545 (3%)

15,586

45–81

9379 (63%)

4694 (31%)

873 (6%)

14,946

82–146

8013 (54%)

5470 (37%)

1326 (9%)

14,809

>146

6603 (44%)

5297 (35%)

3198 (21%)

15,098

1

14,080 (61%)

7377 (32%)

1702 (7%)

23,159

2

9182 (58%)

5195 (33%)

1389 (9%)

15,766

3

7695 (55%)

4574 (33%)

1675 (12%)

13,944

4

3986 (53%)

2408 (32%)

1176 (16%)

7570

1

26,277 (59%)

14,442 (32%)

4163 (9%)

44,882

2

2863 (57%)

1675 (33%)

528 (10%)

5066

3

5229 (55%)

3159 (33%)

1138 (12%)

9526

4

452 (60%)

216 (29%)

83 (11%)

751

Missing

122 (57%)

62 (29%)

30 (14%)

214

1

13,405 (61%)

6963 (32%)

1593 (7%)

21,961

2

6619 (58%)

3745 (33%)

1009 (9%)

11,373

3

6793 (56%)

3952 (33%)

1385 (11%)

12,130

4

8126 (54%)

4894 (33%)

1955 (13%)

14,975

No

34,815 (58%)

19,477 (32%)

5914 (10%)

60,206

Yes

128 (55%)

77 (33%)

28 (12%)

233

TL

7791 (55%)

4570 (32%)

1722 (12%)

14,083

PL

3122 (43%)

2439 (34%)

1622 (23%)

7183

Characteristic
Hospital type

Hospital location

Hospital volume

Clinical T stage

Clinical N stage

Overall clinical stage

Metastases at diagnosis

Treatment modality

(Continues)
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Characteristic

<12.5 miles

12.5–49.9
miles

Nonsurgical treatment

24,030 (61%)

12,545 (32%)

TABLE 1
>50 miles

Total

2598 (7%)

39,173

ET AL.

(Continued)

Treatment modality for patients with T3/T4 disease
(Column %)

(Column %)

(Column %)

Row total

TL

2578 (22.1%)

2001 (28.7%)

1355 (47.5%)

5934

PL

1065 (9.1%)

665 (9.5%)

307 (10.8%)

2037

Nonsurgical treatment

8038 (68.8%)

4316 (61.8%)

1189 (41.7%)

13,543

Column total

11,681

6982

2851

21,514

Abbreviations: PL, partial laryngectomy; TL, total laryngectomy.

3.3

| Stage of laryngeal cancer

3.5 |

Institutional laryngectomy rate

After controlling for age, sex, race, comorbidities, insurance sta-

When controlling for institutional laryngectomy rate there was a

tus, education level, income, hospital type, geographic location,

significant association between travel distance and receipt of lar-

and year at diagnosis, increased travel distance was associated

yngectomy (intermediate vs. short OR 1.27, CI 1.18–1.36, p < 0.001;

with more advanced stage at presentation (Table 2). Patients

long vs. short OR 1.99, CI 1.79–2.21, p < 0.001).

travelling longer distance were more likely to present with stage
3/4 disease (intermediate vs. short OR 1.07, CI 1.02–1.11,
p = 0.001; long vs. short OR 1.26 CI 1.17–1.36, p < 0.001). Long-

3.6 |

Survival analysis

er travel distance was also associated with increased likelihood of
overall stage 4 disease and T4 disease. There was no significant

Overall, increasing travel distance was associated with improved survival

association between travel distance and likelihood of presenting

(intermediate vs. short: HR 0.92, CI 0.9–0.94, p < 0.001; long vs. short: HR

with metastases at diagnosis. In addition, patients who resided in

0.86, CI 0.83–0.90, p < 0.001) (Table 4, Figure 2). As expected, increasing

cities were more likely to present with overall stage 4 disease

clinical stage and increasing T stage were both associated with decreased

compared to those patients who lived in urban areas (OR 0.94

survival. Increasing N stage was also associated with lower survival

0.88–1, CI 0.88–0.99, p = 0.042), but not in rural areas (OR 0.9, CI

(Table 4). Among patients with T1/T2 disease there was no significant

0.78–1.03, p = 0.131). Patients who presented with tumor stage

difference in survival with increase in travel distance. Among patients

4 disease were also more likely to live in cities compared to urban

withT3 disease there was a small, but statistically significant improvement

locations (OR 0.9, CI 0.84–0.98, p = 0.013), but not in rural areas

in survival when traveling intermediate differences compared to short

(OR 0.96, CI 0.81–1.13, p 0.62). There was no significant

(HR 0.93, CI 0.88–0.98, p = 0.009); this improvement did not hold when

association between residence and presence of metastases at

comparing long distances to short (HR 0.92, CI 0.85–1.01, p = 0.067).

presentation.

There were no significant differences in survival when comparing distance
traveled among patients with T4 disease. For patients with T3 disease
there was no significant improvement in survival based on treatment

3.4

| Total laryngectomy

modality. Finally, among patients with T4 disease traveling all distances,
there was a significant improvement in survival when surgical treatment

Of patients that traveled short, intermediate, and long distances,

(partial or total laryngectomy) was the primary treatment modality (partial

8.9%, 12.5%, and 27.3% underwent total laryngectomy respec-

laryngectomy vs. nonsurgical treatment: HR 0.84, CI 0.75–0.94,

tively. After adjustment for relevant covariates, a comparison of

p = 0.002; total laryngectomy vs. nonsurgical treatment: HR 0.75, CI

patients who travelled short distances (<12.5 miles) to those

0.70–0.80, p < 0.001) (Figure 3). This remained true across all distances

traveling intermediate (12.5–49.9 miles) or long (≥50 miles) dis-

for patients who were treated with primary total laryngectomy compared

tances revealed that the latter two groups were more likely to

to nonsurgical management (Table 4).

receive total laryngectomy (intermediate vs. short OR 1.40, CI
1.30–1.50, p < 0.001; long vs. short OR 2.52, CI 2.28–2.79,
p < 0.001) (Table 3). It should be noted that this significant cor-

4 |
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relation between receipt of total laryngectomy and increasing
travel distance was apparent even when controlling for stage at

We elucidated the relationship between travel distance to

presentation. Increasing clinical T‐stage was also associated with

treatment and stage at presentation and risk of undergoing total

receipt of total laryngectomy, as would be expected clinically.

laryngectomy among patients with laryngeal SCC. We found a

MORSE
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TABLE 2

TABLE 3

Odds ratio for presenting at advanced stage

Distance

OR (95% CI)

Odds ratio for receiving total laryngectomy

p value

Overall stage 3/4

7

OR (95% CI)

p value

Distance

<12.5 miles

Ref

12.5–49.9 miles

1.07 (1.02–1.12)

>50 miles

1.26 (1.17–1.36)

<12.5 miles

Ref

0.004

12.5–49.9 miles

1.4 (1.3–1.5)

<0.001

<0.001

>50 miles

2.52 (2.28–2.79)

<0.001

Overall Stage 4

Sex

<12.5 miles

Ref

12.5–49.9 miles

1.07 (1.01–1.12)

0.013

>50 miles

1.19 (1.1–1.29)

<0.001

Tumor Stage 4

Male

Ref

Female

0.85 (0.79–0.91)

<0.001

Race
White

Ref

Black

0.95 (0.88–1.03)

0.239

<12.5 miles

Ref

12.5–49.9 miles

1.11 (1.04–1.18)

0.001

Hispanic

1.11 (0.96–1.27)

0.156

>50 miles

1.5 (1.36–1.65)

<0.001

Other

1.06 (0.89–1.27)

0.521

Metastases at
diagnosis

Age

<12.5 miles

Ref

12.5–49.9 miles

1.12 (0.82–1.53)

0.468

>50 miles

1.26 (0.78–2.06)

0.347

Overall stage 3/4

<50 years

Ref

50–64 years

1.05 (0.95–1.16)

0.331

65–79 years

0.98 (0.87–1.1)

0.705

80 years or more

0.75 (0.64–0.88)

<0.001

Charlson Dey comorbidity score

City

Ref

Urban

0.98 (0.92–1.04)

0.484

Rural

0.94 (0.83–1.07)

0.374

Overall stage 4

0

Ref

1

1.62 (1.51–1.73)

<0.001

2

1.67 (1.49–1.87)

<0.001

≥3

1.45 (1.21–1.73)

<0.001

City

Ref

Urban

0.94 (0.88–0.99)

0.042

Private insurance

Ref

Rural

0.9 (0.78–1.03)

0.131

Uninsured

0.81 (0.72–0.91)

<0.001

Medicaid

1.14 (1.01–1.29)

0.034

Medicare/OtherGov

0.9 (0.8–1.02)

0.103

0.91 (0.74–1.12)

0.374

Insurance type

Tumor stage 4
City

Ref

Urban

0.9 (0.84–0.98)

0.013

Unknown

Rural

0.96 (0.81–1.13)

0.616

Urban status

Metastases at
diagnosis
City

Ref

Urban

0.73 (0.49–1.1)

0.134

Rural

0.52 (0.18–1.47)

0.217

Abbreviations: CI, confidence interval; OR, odds ratio.

City

Ref

Urban

0.9 (0.82–0.98)

0.015

Rural

0.76 (0.63–0.91)

0.004

Unknown

1.03 (0.82–1.28)

0.82

Education attainment
>20% with HS degree

Ref

>20% without HS
degree

1.12 (1.05–1.19)

0.001

correlation between increased travel distance (12.5–49.9 miles
and ≥50 miles subgroups) and increased cancer stage and in-

Income

creased rates of laryngectomy when compared to those patients

>30,000

Ref

traveling short distances (<12.5 miles). This relationship between

<$30,000

0.95 (0.88–1.03)

distance and receipt of laryngectomy remained even when controlling for stage at time of diagnosis. We also found that patients

0.251

(Continues)
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TABLE 4

(Continued)
OR (95% CI)

ET AL.

Survival outcomes
HR (95% CI)

p value

p value

Distance

Hospital type

<12.5 miles

Ref

<0.001

12.5–49.9 miles

0.92 (0.90–0.94)

p < 0.001

0.48 (0.44–0.52)

<0.001

>50 miles

0.86 (0.83–0.9)

p < 0.001

INCC

0.54 (0.48–0.6)

<0.001

Unknown

0.83 (0.61–1.12)

0.224

Academic/NCI CCC

Ref

Community center

0.38 (0.32–0.44)

CCC

Hospital volume
<47

Ref

47–87

1.04 (0.94–1.15)

0.429

88–163

1.13 (1.02–1.26)

0.017

>163

1.53 (1.37–1.7)

<0.001

Clinical T stage
1

Ref

2

1.62 (1.15–2.28)

0.006

3

4.49 (3.26–6.19)

<0.001

4

17.51 (12.67–24.19)

<0.001

Clinical stage group

Overall clinical stage
1

Ref

2

1.50 (1.38–1.64)

p < 0.001

3

1.76 (1.62–1.92)

p < 0.001

4

1.76 (1.60–1.94)

p < 0.001

Clinical T stage
1

Ref

2

1.04 (0.96–1.13)

p = 0.298

3

1.14 (1.06–1.24)

p = 0.001

4

1.39 (1.28–1.52)

p < 0.001

Clinical N stage
0

Ref

1

1.11 (1.06–1.16)

p < 0.001

2

1.30 (1.23–1.38)

p < 0.001

1

Ref

2

2.18 (1.51–3.14)

<0.001

3

2.20 (2.00–2.42)

p < 0.001

3

2.84 (2.02–3.99)

<0.001

Missing

1.41 (1.20–1.66)

p < 0.001

4

2.14 (1.52–3)

<0.001

Stage T1/T2

Metastases at diagnosis
No metastases

Ref

Metastases

1.51 (1.08–2.11)

0.015

<12.5 miles

Ref

12.5–49.9 miles

0.98 (0.95–1.02)

p = 0.419

>50 miles

0.94 (0.88–1.00)

p = 0.066

Stage T3
<12.5 miles

Ref

presenting with overall stage 4 disease and T4 stage disease were

12.5–49.9 miles

0.93 (0.88–0.98)

p = 0.009

more likely to live in cities compared to urban areas, however,

>50 miles

0.92 (0.85–1.01)

p = 0.067

there was no significant difference in presentation at T4 or overall

All T3 patients

stage 4 disease between patients residing in cities versus rural

Nonsurgical treatment

Ref

did not appear to impart a protective effect on survival, while

PL

1.00 (0.93–1.07)

p = 1.000

among patients with T3 disease only those traveling intermediate

TL

0.98 (0.92–1.04)

p = 0.519

areas. Lastly, among patients with T1/T2 disease travel distance

distances had improved survival compared to short travel distance. There were no significant differences in survival between

All T3 patients traveling <12.5 miles
Nonsurgical treatment

Ref

PL

1.00 (0.91–1.10)

p = 0.976

TL

0.97 (0.89–1.06)

p = 0.507

travel distance groupings for patients with T4 disease. Finally, we
found that patients with T4 disease who underwent primary
surgical management (total laryngectomy) had significantly improved survival compared to those who underwent nonsurgical
management (definitive chemoradiation). There were no sig-

All T3 patients traveling 12.5–49.9 miles
Nonsurgical treatment

Ref

PL

1.01 (0.89–1.15)

p = 0.823

TL

1.00 (0.90–1.11)

p = 0.967

nificant differences in survival between surgical and nonsurgical
treatments among patients with T3 disease. While these findings
can be partially explained by the fact that patients who live
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TABLE 4

9

(Continued)
HR (95% CI)

p value

All T3 patients traveling >50 miles
Nonsurgical treatment

Ref

PL

1.02 (0.83–1.25)

p = 0.868

TL

1.03 (0.88–1.20)

p = 0.720

Stage T4
<12.5 miles

Ref

12.5–49.9 miles

0.94 (0.88–1.01)

p = 0.078

>50 miles

0.97 (0.87–1.07)

p = 0.542

All T4 patients
Nonsurgical treatment

Ref

PL

0.84 (0.75–0.94)

p = 0.002

TL

0.75 (0.70–0.80)

p < 0.001

F I G U R E 2 Overall survival by travel distance compared to short
distance, patients traveling medium and long distances had improved
overall survival (p = 0.01 and p = 0.02 for medium and long distance
respectively)

All T4 patients traveling <12.5 miles
Nonsurgical treatment

Ref

PL

0.80 (0.69–0.93)

p = 0.005

TL

0.75 (0.69–0.82)

p < 0.001

All T4 patients traveling 12.5–49.9 miles
Nonsurgical treatment

Ref

PL

0.99 (0.81–1.20)

p = 0.881

TL

0.79 (0.71–0.89)

p < 0.001

All T4 patients traveling >50 miles
Nonsurgical treatment

Ref

PL

0.68 (0.49–0.94)

p = 0.021

TL

0.69 (0.57–0.82)

p < 0.001

Abbreviations: CI, confidence interval; HR, hazard ratio; PL, partial
laryngectomy; TL, total laryngectomy.

further from care centers are more likely to present at advanced
stages of disease (and therefore may not be candidates for organ

F I G U R E 3 Overall survival by treatment modality across all travel
distances, patients with stage T4 disease had better overall survival
with surgical treatment (partial laryngectomy and total laryngectomy)
compared to nonsurgical treatment (p = 0.002 and p < 0.001 for
partial laryngectomy and total laryngectomy respectively)

preservation therapy), the results of this study suggest the presence of additional driving factors in determining both survival as

assessing outcomes among patients with HPV negative disease found

well as which patients undergo total laryngectomy.

an association between high volume centers and improved survival,

It is unclear why patients with T1/T2 disease traveling long dis-

with high volume academic centers exhibiting the greatest degree in
28

tances (compared to short or intermediate distances) and patients

improvement.

with T3 disease traveling intermediate distances (compared to short

patients who are able to travel long distances therefore choose to. It

or long distances) had better overall survival. A possible explanation is

is also possible that when given the option, patients may choose total

that patients are being preferentially referred to centers of excellence

laryngectomy over organ preservation therapy secondary to potential

or centers with high volume head and neck pathology and treatment

issues with compliance and availability of and access to necessary

which likely impact survival. We found that high volume centers

resources during treatment. Therefore, the potential for referral bias,

treated the highest proportion of advanced‐stage disease patients

particularly to high‐volume centers must be considered when inter-

and given that there were no significant differences in presentation at

preting these results. Alternatively, it may be that patients presenting

advanced (stage 4) stage disease among patients living in cities

at earlier stages for nonsurgical management have delays or breaks in

compared to rural areas, it appears that patients are preferentially

treatment with resulting residual or recurrent disease necessitating

traveling to high volume centers or “centers of excellence.” A study

surgical salvage. Interestingly, Gourin et al.

Alternatively, it may be that healthier, more robust

29

found that there was
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not a significant association between travel distance and patient

life are well documented38 and patients routinely require specialized

drop‐out rates, but did note increased drop‐out rates in the

support services following either treatment modality. Thus, increased

uninsured.

travel distance may present a barrier to the utilization of these ser-

Compliance during treatment is vital to ensuring the best possi-

vices with significant impact on quality of life and should be ad-

ble oncologic outcome and is positively associated with survival in

dressed when considering treatment approaches. Despite typically

patients with HNSCC. 30 A 2015 study of HNSCC patients treated at

requiring less frequent health care visits than organ‐preserving

the University of Kansas Medical Center observed that patients

therapy, the need for future services after total laryngectomy

traveling >200 miles to care had decreased compliance with post-

should be taken into account during medical decision‐making.

treatment follow‐up. This intrinsically makes sense, as travel over

To our knowledge, this is the first study to evaluate the re-

great distances would presumably require more resources, which

lationship between travel distance and receipt of laryngectomy.

patients may not have, and while this study was isolated to one

Other studies have described the association between increased

treatment facility, it is likely that similar patterns may be observed in

travel distance to treatment and stage of presentation and survival

other parts of the country. Subsequently, concerns regarding com-

(specifically that increased travel distance is associated with in-

pliance with treatment may have increased influence in the decision‐

creased T stage at presentation),39 however, the effect on rates of

making process.

laryngectomy has been previously unstudied. Some explanations for

The currently available data on travel distance to treatment and

our findings may be related to implicit biases held by physicians

disease‐related outcomes is conflicting, with some studies reporting

(concerns regarding patient understanding of disease and natural

improved survival among patients traveling long distances. This

course, anticipated concerns regarding compliance with nonsurgical

phenomena has been described for patients undergoing phase II

treatment, assumptions regarding financial and social support struc-

clinical trials and surgical resection of various gastrointestinal cancers

tures enabling daily therapy, etc.) and patients. Our additional find-

and in large, national database retrospective reviews of patients

ings, such as slightly higher rates of laryngectomy among those with

treated for Head and Neck cancer.

31,32

However, other recent stu-

Medicaid and those residing in areas with low educational attain-

dies have shown long travel distances (>200 miles) to have a negative

ment, also point to these and other potential causes. Though not

effect on treatment and/or survival.

4,8,13

In our analysis, we found increasing travel distance to increase
the odds of receipt of total laryngectomy. Furthermore, when com-

explored in the present study, these results highlight the need to
examine broader disparities present within the healthcare system and
equalize access to health care for all patients.

paring outcomes by treatment modality across all distances and be-

This study was limited by the fact that travel distance is calcu-

tween subgroups, we found total laryngectomy to be associated with

lated by zip code of residence to zip code of treating facility. This may

significantly improved survival compared to nonsurgical treatment for

have underestimated the time and burden placed on those in urban

patients with T4 disease. This first suggests that physicians may be

settings who rely on public transportation and may significantly un-

preferentially choosing definitive surgery over nonsurgical manage-

derestimate time and other resources spent during travel. This may

ment for patients traveling greater distances. The second implication

be another important metric to evaluate when assessing the impact

is that patients undergoing primary laryngectomy for advanced stage

of travel on disease outcomes. Additionally, travel distance and lo-

tumors (specifically stage T4) have improved survival compared to

cation of residence cannot account for other factors and obstacles

nonsurgical treatment. This has been borne out in previous studies

that may prevent patients from easily accessing care (e.g., cost, ac-

evaluating outcomes following definitive treatment of advanced (T4)

cess to transportation itself, ability to miss work for appointments).

laryngeal cancers, which have shown improved survival with primary

There is also a potential for patient choice or physician protocols,

laryngectomy compared to organ preservation therapy. 33–35 Thus in

which may influence results and could not be accounted for via a

this context, greater travel distance imparts a protective effect on

study of this nature. Finally, large secondary data sets are by nature

survival and further supports the notion of centralization of care.

limited in the data available for analysis, and there may be variables

Based on current available evidence, recent recommendations have

missing that impact outcomes and could not be examined.

encouraged centralization of cancer treatment to allow for more
consolidated care, improved resource allocation and support, and
ultimately, improved outcomes.

16,33,36

5 |

CONCLUSION

While the centralization of care has many advantages, it may
potentially further strain the social and financial resources of already

Our study indicates that increased travel distance to care is as-

at‐risk patients by increasing their travel distance. It may then force

sociated with more advanced stage at diagnosis in patients with

patients to choose convenience over higher quality care and forgo

laryngeal SCC, with increased rate of laryngectomy, and with

treatment and posttreatment surveillance at higher volume hospitals

improved survival among certain subgroups of patients. Even

with better outcomes.

37

These potential barriers to advanced care

when controlling for stage at the time of diagnosis, increasing

and their impact on posttreatment surveillance must be taken into

travel distance is associated with increased rates of total lar-

consideration during the decision making process. The effects of total

yngectomy suggesting the presence of other currently unknown

laryngectomy and concurrent chemoradiation therapy on quality of

driving factors. As centralization of cancer care continues
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patients may travel even greater distances further exacerbating

3.

the possible burdens associated with travel (e.g. access to support, cost, and convenience). Health care providers and systems
need to remain cognizant of the impact of these factors on

4.

treatment decisions and outcomes. Health policy efforts for patients with laryngeal cancer should account for disparities resulting from difficulty accessing care and recognize the impact of
travel distance on treatment outcomes.
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The data used in the study are derived from a deidentified NCDB file.
The American College of Surgeons and the Commission on Cancer

7.

have not verified and are not responsible for the analytic or statistical
methodology employed, or the conclusions drawn from these data by
the investigator.

8.
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PRE CIS
Increased travel distance to care is associated with increased stage of
disease at presentation and increased risk of undergoing total lar-

10.

yngectomy but may have a protective effect upon survival among
patients with advanced laryngeal disease. Preferential use of primary
surgical management of advanced disease may account for some of

11.

these disparities in outcomes.
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